These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
364 related articles for article (PubMed ID: 36499601)
21. CRISPR/Cas9-A Promising Therapeutic Tool to Cure Blindness: Current Scenario and Future Prospects. Ahmad I Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232782 [TBL] [Abstract][Full Text] [Related]
22. A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells. Geng BC; Choi KH; Wang SZ; Chen P; Pan XD; Dong NG; Ko JK; Zhu H Acta Pharmacol Sin; 2020 Nov; 41(11):1427-1432. PubMed ID: 32555510 [TBL] [Abstract][Full Text] [Related]
23. Induced pluripotent stem cells (iPSC)-derived retinal cells in disease modeling and regenerative medicine. Rathod R; Surendran H; Battu R; Desai J; Pal R J Chem Neuroanat; 2019 Jan; 95():81-88. PubMed ID: 29448001 [TBL] [Abstract][Full Text] [Related]
24. CRISPR-Cas9-Based Genome Editing of Human Induced Pluripotent Stem Cells. Giacalone JC; Sharma TP; Burnight ER; Fingert JF; Mullins RF; Stone EM; Tucker BA Curr Protoc Stem Cell Biol; 2018 Feb; 44():5B.7.1-5B.7.22. PubMed ID: 29512106 [TBL] [Abstract][Full Text] [Related]
25. Induced Pluripotent Stem Cells and CRISPR-Cas9 Innovations for Treating Alpha-1 Antitrypsin Deficiency and Glycogen Storage Diseases. Walsh C; Jin S Cells; 2024 Jun; 13(12):. PubMed ID: 38920680 [TBL] [Abstract][Full Text] [Related]
26. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system. Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575 [TBL] [Abstract][Full Text] [Related]
27. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells. Kim EJ; Kang KH; Ju JH Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282 [TBL] [Abstract][Full Text] [Related]
28. Potential of Gene Editing and Induced Pluripotent Stem Cells (iPSCs) in Treatment of Retinal Diseases. Chuang K; Fields MA; Del Priore LV Yale J Biol Med; 2017 Dec; 90(4):635-642. PubMed ID: 29259527 [TBL] [Abstract][Full Text] [Related]
29. Harnessing the Potential of Human Pluripotent Stem Cells and Gene Editing for the Treatment of Retinal Degeneration. Ovando-Roche P; Georgiadis A; Smith AJ; Pearson RA; Ali RR Curr Stem Cell Rep; 2017; 3(2):112-123. PubMed ID: 28596937 [TBL] [Abstract][Full Text] [Related]
30. Genome editing, a superior therapy for inherited retinal diseases. Yan AL; Du SW; Palczewski K Vision Res; 2023 May; 206():108192. PubMed ID: 36804635 [TBL] [Abstract][Full Text] [Related]
31. Gene Editing and Human Pluripotent Stem Cells: Tools for Advancing Diabetes Disease Modeling and Beta-Cell Development. Millette K; Georgia S Curr Diab Rep; 2017 Oct; 17(11):116. PubMed ID: 28980194 [TBL] [Abstract][Full Text] [Related]
32. Site-Specific Genome Engineering in Human Pluripotent Stem Cells. Merkert S; Martin U Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347935 [TBL] [Abstract][Full Text] [Related]